Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus

Beam Therapeutics BEAM incurred a loss of $1.18 per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of $1.00. The company had reported a loss of $1.00 per

Zacks 
0 05.08.26